Budget impact of sirolimus
1 evidence topic · 1 source
Summary
The sponsor presented a potential annual pricing range of approximately $100,000 to $200,000 per patient. The presentation does not identify that range as ASP or WAC. A potential annual price range alone does not establish payer budget impact, which also depends on eligible population, uptake, treatment duration, reimbursement, and changes in other healthcare utilization. No QTORIN-specific budget impact model is included in the evidence collected for this report.